Ethanone, 1-(5-bromo-4-iodo-1H-pyrrolo[2,3-b]pyridin-1-yl)- | 1092580-05-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: Ethanone, 1-(5-bromo-4-iodo-1H-pyrrolo[2,3-b]pyridin-1-yl)-
• 英文别名: 1-(5-bromo-4-iodopyrrolo[2,3-b]pyridin-1-yl)ethanone
• CAS: 1092580-05-6
• 化学式: C₉H₆BrIN₂O
• 分子量: 364.96
• InChiKey: VXWYRZIYASZKTB-UHFFFAOYSA-N

物化性质

• 沸点：
  389.2±37.0 °C(Predicted)
• 密度：
  2.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：BORAGEN INC

  公开号：WO2020232470A1

  公开（公告）日：2020-11-19

  The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

  本发明描述了新型化合物，或其药用可接受的盐，包含它们的药物组合物，以及它们的医疗用途。本发明的化合物具有作为Janus激酶（JAK）抑制剂的活性，并且在治疗或控制炎症、自身免疫疾病、癌症和其他需要调节JAK的紊乱和指示症状方面是有用的。本文还描述了通过给予本文描述的化合物来治疗炎症、自身免疫疾病、癌症和其他容易受到JAK抑制的情况的方法。
• SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS
  申请人：Blaney Jeffrey M.

  公开号：US20090005356A1

  公开（公告）日：2009-01-01

  Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.

  本文提供了取代的吡咯吡啶杂环和取代的吡唑吡啶杂环，以及包含这些杂环的制药组合物以及使用这些杂环治疗疾病的方法。本文所披露的杂环可作为激酶调节剂，并在治疗癌症、过敏、哮喘、炎症、阻塞性呼吸道疾病、自身免疫疾病、代谢性疾病、感染、中枢神经系统疾病、脑肿瘤、肥胖症、哮喘、血液疾病、退行性神经疾病、心血管疾病或与血管生成、新生血管或血管生成有关的疾病中具有实用价值。
• CHEMICAL COMPOUNDS
  申请人：Boragen, Inc.

  公开号：EP3969458A1

  公开（公告）日：2022-03-23
• US8158647B2
  申请人：——

  公开号：US8158647B2

  公开（公告）日：2012-04-17